TITLE

Consumo y gasto de fármacos antipsicóticos

PUB. DATE
March 2005
SOURCE
Actas Espanolas de Psiquiatria;mar2005, Vol. 33 Issue 2, p64
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
INTRODUCTION: In recent years, new atypical antipsychotic drugs have been marketed. This study aims to analyze the evolution of the consumption pattern and pharmaceutical cost of the antipsychotic drugs during the last years and the impact that the new atypical antipsychotic drugs have had. METHODS: Based on the ECOM database of the Ministry of Health and Consumer Affairs of Spain, the sales data of the antipsychotic drugs in Catalonia during the 1990-2001 period have been chosen. The drugs have been classified into typical or classical and atypical. Consumption data have been expressed in daily defined dose (DDD) per 1,000 inhabitants and per day of treatment (DID), and cost data in constant euros. RESULTS: Antipsychotic consumption increased from 3.31 DID in 1990 to 6.04 DID in 2001. Typical drugs consumption decreased (from 100 % consumption in 1990 to 46 % in 2001) and that of the atypical ones increased (from 1% consumption in the year 1993 to 54% in the year 2001). A change in the use pattern of different drugs is verified. In the year 1990, the most consumed drugs were flupenthixol (0.86 DID) and haloperidol (0.67 DID), and in the year 2001 olanzapine (1.69 DID) and risperidone (1.30 DID). The drugs with a greater increase in consumption were olanzapine, which multiplied its consumption five fold from 1997 to 2001 and risperidone, which multiplied it by 20 from 1994 to 2001. During the study period, the cost increased 13 times, above all due to increase in cost of atypical antipsychotics (from less than 1 % of the total cost in 1993 to 92 % of the total cost in 2001). The DDD cost of antipsychotics increased (6.48 euros in 1990 and 20.31 euros in 2001). However, that of the typical antipsychotics decreased (6.48 euros in 1990 and 4.62 euros in 2001) and that of the atypical ones increased (2.06 euros in 1993 and 15.69 euros in 2001). CONCLUSION: The marketing of the new atypical antipsychotic drugs has had an extraordinary impact on antipsychotic drug consumption and cost. The cost/effectiveness ratio of the new atypical antipsychotic drugs in the clinical practice should be evaluated to determine the economic resources aimed at costs of the different antipsychotic drugs.
ACCESSION #
16782677

 

Related Articles

  • Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Sultana, Janet; Hurtado, Isabel; Bejarano-Quisoboni, Daniel; Giorgianni, Francesco; Huybrechts, Krista F.; Lu, Zhigang; Patorno, Elisabetta; Sanfélix-Gimeno, Gabriel; Tari, Daniele Ugo; Trifirò, Gianluca // European Journal of Clinical Pharmacology;Jul2019, Vol. 75 Issue 7, p1005 

    Purpose: The aim of the present study was to describe antipsychotic utilization patterns among patients with schizophrenic disorder in Italy, Spain, the UK, and the USA. Methods: A retrospective cohort study was conducted. Patients aged 15 and over with schizophrenic disorder were identified in...

  • Post-marketing surveillance. Culliton, Barbara J.; Waterfall, Wallace K. // British Medical Journal;5/10/1980, Vol. 280 Issue 6224, p1175 

    Focuses on the system for monitoring the use and effects of prescription drugs following marketing strategy in the United States. Methods of post-marketing surveillance of pharmaceutical; Emphasis of the Food and Druf Administration on pre-marketing phases of drug development; Creation of the...

  • Impact of standard of care for psychosis in Parkinson disease. Thomsen, T. R.; Panisset, M.; Suchowersky, O.; Goodridge, A.; Meridis, T.; Lang, A. E. // Journal of Neurology, Neurosurgery & Psychiatry;Dec2008, Vol. 79 Issue 12, p1413 

    The article presents a study that evaluates patients with idiopathic Parkinson Disease (PD) using separate investigator-initiated protocol. Results showed that 10 patients who had their anti-PD medication regimen adjusted showed clear improvement, eliminating the need for neuroleptic treatment....

  • Perphenazine.  // AHFS Consumer Medication Information;Aug2020, p1 

    Perphenazine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Perphenazine is also used to control severe nausea and vomiting in adults. Perphenazine is in a class of...

  • DID YOU KNOW?  // HealthLeaders Magazine;Mar2009, Vol. 12 Issue 3, p14 

    The article looks at the higher spending of Americans on prescription drugs compared to other industrialized countries in Europe. According to a report, patients in the U.S. spend each year $98 billion on medications which are more than those of other countries. Also included is an overview of...

  • Postmarketing surveillance of sofosbuvir in Egypt.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p3 

    The article reports on the clarification of the Technical Committee at the Central Administration of Pharmaceutical Affairs on the requirements for postmarketing surveillance of sofosbuvir for hepatitis C in Egypt.

  • Paliperidone.  // AHFS Consumer Medication Information;Aug2020, p1 

    Paliperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Paliperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of...

  • Asenapine.  // AHFS Consumer Medication Information;Aug2020, p1 

    Asenapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Asenapine is used alone or in combination with other medications to treat or prevent episodes of mania (frenzied,...

  • Trifluoperazine.  // AHFS Consumer Medication Information;Aug2020, p1 

    Trifluoperazine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Trifluoperazine is also used on a short-term basis to treat anxiety in people who have not been helped by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics